Integra Lifesciences Holdings Stock Fundamentals
| IART Stock | USD 23.00 0.07 0.31% |
Integra LifeSciences Holdings fundamentals help investors to digest information that contributes to Integra LifeSciences' financial success or failures. It also enables traders to predict the movement of Integra Stock. The fundamental analysis module provides a way to measure Integra LifeSciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Integra LifeSciences stock.
At this time, Integra LifeSciences' Total Operating Expenses is comparatively stable compared to the past year. Net Income Applicable To Common Shares is likely to gain to about 218 M in 2024, whereas Income Before Tax is likely to drop slightly above 51.6 M in 2024. Integra | Select Account or Indicator |
Integra LifeSciences Holdings Company Profit Margin Analysis
Integra LifeSciences' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Integra LifeSciences Profit Margin | (0) % |
Most of Integra LifeSciences' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Integra LifeSciences Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Integra Pretax Profit Margin
Pretax Profit Margin |
|
Based on the latest financial disclosure, Integra LifeSciences Holdings has a Profit Margin of -0.0042%. This is 99.96% lower than that of the Health Care Equipment & Supplies sector and 99.92% lower than that of the Health Care industry. The profit margin for all United States stocks is 99.67% lower than that of the firm.
Integra LifeSciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Integra LifeSciences's current stock value. Our valuation model uses many indicators to compare Integra LifeSciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Integra LifeSciences competition to find correlations between indicators driving Integra LifeSciences's intrinsic value. More Info.Integra LifeSciences Holdings is rated fifth overall in return on equity category among its peers. It is rated fourth overall in return on asset category among its peers . At this time, Integra LifeSciences' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Integra LifeSciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Integra Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Integra LifeSciences' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Integra LifeSciences could also be used in its relative valuation, which is a method of valuing Integra LifeSciences by comparing valuation metrics of similar companies.Integra LifeSciences is currently under evaluation in profit margin category among its peers.
Integra LifeSciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Integra LifeSciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Integra LifeSciences' managers, analysts, and investors.Environmental | Governance | Social |
Integra Fundamentals
| Return On Equity | -0.0042 | ||||
| Return On Asset | 0.0302 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 3.48 B | ||||
| Shares Outstanding | 77.16 M | ||||
| Shares Owned By Insiders | 3.21 % | ||||
| Shares Owned By Institutions | 93.14 % | ||||
| Number Of Shares Shorted | 5.18 M | ||||
| Price To Earning | 26.94 X | ||||
| Price To Book | 1.16 X | ||||
| Price To Sales | 1.13 X | ||||
| Revenue | 1.54 B | ||||
| Gross Profit | 982.03 M | ||||
| EBITDA | 383.57 M | ||||
| Net Income | 67.74 M | ||||
| Cash And Equivalents | 451.52 M | ||||
| Cash Per Share | 5.41 X | ||||
| Total Debt | 1.68 B | ||||
| Debt To Equity | 1.03 % | ||||
| Current Ratio | 3.85 X | ||||
| Book Value Per Share | 19.73 X | ||||
| Cash Flow From Operations | 139.96 M | ||||
| Short Ratio | 7.11 X | ||||
| Earnings Per Share | (0.09) X | ||||
| Price To Earnings To Growth | 0.77 X | ||||
| Target Price | 28.11 | ||||
| Number Of Employees | 3.95 K | ||||
| Beta | 1.08 | ||||
| Market Capitalization | 1.77 B | ||||
| Total Asset | 3.78 B | ||||
| Retained Earnings | 946.86 M | ||||
| Working Capital | 751.06 M | ||||
| Current Asset | 438.5 M | ||||
| Current Liabilities | 139.13 M | ||||
| Net Asset | 3.78 B |
About Integra LifeSciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Integra LifeSciences Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Integra LifeSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Integra LifeSciences Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 8.5 M | 5.3 M | |
| Total Revenue | 1.5 B | 1.6 B | |
| Cost Of Revenue | 653.2 M | 685.8 M | |
| Stock Based Compensation To Revenue | 0.01 | 0.01 | |
| Sales General And Administrative To Revenue | 0.54 | 0.57 | |
| Research And Ddevelopement To Revenue | 0.11 | 0.14 | |
| Capex To Revenue | 0.04 | 0.07 | |
| Revenue Per Share | 19.72 | 20.71 | |
| Ebit Per Revenue | 0.07 | 0.08 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.